跳转到内容

乌美溴铵

维基百科,自由的百科全书
乌美溴铵
臨床資料
商品名英语Drug nomenclatureIncruse Ellipta
其他名稱GSK573719A、芜地溴铵
核准狀況
给药途径吸入(DPI英语Dry powder inhaler
ATC碼
法律規範狀態
法律規範
藥物動力學數據
血漿蛋白結合率~89%[2]
药物代谢CYP2D6
生物半衰期11 hours
排泄途徑粪便(58%)和尿液(22%)
识别信息
  • Diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol bromide
CAS号869113-09-7
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard英语CompTox Chemicals Dashboard (EPA)
ECHA InfoCard100.166.375 編輯維基數據鏈接
化学信息
化学式C29H34BrNO2
摩尔质量508.50 g·mol−1
3D模型(JSmol英语JSmol
  • OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2.[Br-]
  • InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1
  • Key:PEJHHXHHNGORMP-UHFFFAOYSA-M

乌美溴铵INN:umeclidinium bromide;商品名:Incruse Ellipta),或译芜地溴铵,是一种长效毒蕈碱拮抗剂,被批准用于慢性阻塞性肺病(COPD)的维持治疗。[2]它还被批准与维兰特罗乌美溴铵/维兰特罗)联合用于该适应症[3][4]以及作为糠酸氟替卡松/乌美溴铵/维兰特罗的三重疗法组合。[5]

它被列入世界卫生组织的基本药物清单[6]2020年,它是美国第245位最常用处方药物,处方数量超过100万张。[7][8]

参考资料

[编辑]
  1. ^ Prescription medicines: registration of new chemical entities in Australia, 2014. Therapeutic Goods Administration (TGA). 21 June 2022 [10 April 2023]. (原始内容存档于2023-04-10). 
  2. ^ 2.0 2.1 Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. [22 February 2016]. (原始内容 (PDF)存档于10 July 2018). 
  3. ^ Feldman GJ, Edin A. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Therapeutic Advances in Respiratory Disease. December 2013, 7 (6): 311–9. PMID 24004659. S2CID 5744282. doi:10.1177/1753465813499789. 
  4. ^ FDA Approves Umeclidinium and Vilanterol Combo for COPD. Medscape. December 18, 2013 [2024-03-07]. (原始内容存档于2017-09-24). 
  5. ^ TRELEGY ELLIPTA Package Insert (PDF). GlaxoSmithKline. September 2017 [11 July 2020]. (原始内容存档 (PDF)于2020-07-12). 
  6. ^ World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. hdl:10665/345533可免费查阅. WHO/MHP/HPS/EML/2021.02. 
  7. ^ The Top 300 of 2020. ClinCalc. [7 October 2022]. (原始内容存档于2021-02-12). 
  8. ^ Umeclidinium - Drug Usage Statistics. ClinCalc. [7 October 2022]. (原始内容存档于2023-09-24). 

外部链接

[编辑]
  • Umeclidinium. Drug Information Portal. U.S. National Library of Medicine. [2024-03-07]. (原始内容存档于2022-12-01). 
  • Umeclidinium bromide. Drug Information Portal. U.S. National Library of Medicine. [2024-03-07]. (原始内容存档于2022-06-02).